{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T01:39:08Z","timestamp":1768700348476,"version":"3.49.0"},"reference-count":49,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Canadian Initiative for Outcomes in Rheumatology cAre","award":["2015-001"],"award-info":[{"award-number":["2015-001"]}]},{"name":"Alberta SPOR SUPPORT Unit","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,2,26]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>Patients with inflammatory conditions are at high risk for cardiovascular (CV) disease. Despite such elevated risk, their CV risk factors are suboptimally managed.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effect of a pharmacist-led intervention on CV risk in patients with inflammatory conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Prospective pre\u2013postintervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>17 community pharmacies across Alberta.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Population<\/jats:title>\n                    <jats:p>Adults with inflammatory conditions (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout, systemic lupus erythematosus, psoriasis vulgaris) who had at least one uncontrolled risk factor (A1C, blood pressure, LDL-cholesterol or current tobacco users).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>All patients enrolled in the study received: physical and laboratory assessment, individualised CV risk assessment and education regarding this risk, treatment recommendations, prescription adaptation and prescribing where necessary to meet treatment targets, regular communication with the patient\u2019s treating physician(s) and regular follow-up with all patients every month for 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>Primary: change in estimated CV risk (risk of a major CV event in the next 10 years) after 6 months. Secondary: change in individual risk factors (blood pressure, LDL-cholesterol, A1C and tobacco cessation) over a 6-month period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We enrolled 99 patients. The median age was 66.41 years (IQR 57.64\u201372.79), More than half of them (61%) were female and more than three-quarters (86%) were Caucasians. After adjusting for age, sex and ethnicity and centre effect, there was a reduction of 24.5% in CV risk (p&lt;0.001); including a reduction of 0.3\u2009mmol\/L in LDL-c (p&lt;0.001), 10.7\u2009mm Hg in systolic blood pressure (p&lt;0.001), 1.25% in A1C (p&lt;0.001). There was a non-significant trend towards tobacco cessation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This is the first study on CV risk reduction in patients with inflammatory conditions in a community pharmacy setting. R\n                      <jats:sub>x<\/jats:sub>\n                      IALTA provides evidence for the benefit of pharmacist care on global cardiovascular risk reduction as well as the individual cardiovascular risk factors in patients with inflammatory conditions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03152396\">NCT03152396<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-043612","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T13:00:13Z","timestamp":1616590813000},"page":"e043612","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["R\n                    <sub>x<\/sub>\n                    IALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre\u2013post intervention study"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03152396","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3984-3542","authenticated-orcid":false,"given":"Yazid N","family":"Al Hamarneh","sequence":"first","affiliation":[{"name":"EPICORE Centre, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Marra","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Otago, Dunedin, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gniadecki","sequence":"additional","affiliation":[{"name":"Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Keeling","sequence":"additional","affiliation":[{"name":"Rheumatology, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Morgan","sequence":"additional","affiliation":[{"name":"Foothills Medical Centre, Calgary, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Tsuyuki","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"2025120520060893000_11.3.e043612.1","unstructured":"WHO . Cardiovascular diseases, 2017. Available: http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/ [Accessed June 9, 2020]."},{"key":"2025120520060893000_11.3.e043612.2","unstructured":"Government of Canada . Report from the Canadian chronic disease surveillance system: heart disease in Canada, 2018, 2018. Available: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/report-heart-disease-Canada-2018.html [Accessed June 9, 2020]."},{"key":"2025120520060893000_11.3.e043612.3","unstructured":"The Arthritis Society . Arthritis in Canada, facts and figures, 2020. Available: https:\/\/arthritis.ca\/about-arthritis\/what-is-arthritis\/arthritis-facts-and-figures [Accessed June 9, 2020]."},{"key":"2025120520060893000_11.3.e043612.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.02.015"},{"key":"2025120520060893000_11.3.e043612.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.113696"},{"key":"2025120520060893000_11.3.e043612.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204792"},{"key":"2025120520060893000_11.3.e043612.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210275"},{"key":"2025120520060893000_11.3.e043612.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.20853"},{"key":"2025120520060893000_11.3.e043612.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.20855"},{"key":"2025120520060893000_11.3.e043612.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.20878"},{"key":"2025120520060893000_11.3.e043612.11","first-page":"30","article-title":"A primary care cardiovascular risk reduction clinic in Canada was more effective and no more expensive than usual on-demand primary care--a randomised controlled trial","volume":"18","author":"Mills","year":"2010","journal-title":"Health Soc Care Community"},{"key":"2025120520060893000_11.3.e043612.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01889.x"},{"key":"2025120520060893000_11.3.e043612.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2005.01549.x"},{"key":"2025120520060893000_11.3.e043612.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1747-9"},{"key":"2025120520060893000_11.3.e043612.15","unstructured":"Canadian Institute for Health Information . Physicians in Canada, 2018, 2019. Available: https:\/\/www.cihi.ca\/sites\/default\/files\/document\/physicians-in-canada-2018.pdf [Accessed June 9, 2020]."},{"key":"2025120520060893000_11.3.e043612.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.23650"},{"key":"2025120520060893000_11.3.e043612.17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.699579"},{"key":"2025120520060893000_11.3.e043612.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204024"},{"key":"2025120520060893000_11.3.e043612.19","doi-asserted-by":"publisher","DOI":"10.1186\/ar2098"},{"key":"2025120520060893000_11.3.e043612.20","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X16664306"},{"key":"2025120520060893000_11.3.e043612.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.34524"},{"key":"2025120520060893000_11.3.e043612.22","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22091"},{"key":"2025120520060893000_11.3.e043612.23","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.39165","article-title":"Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients","volume":"67","author":"Liao","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025120520060893000_11.3.e043612.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.113696"},{"key":"2025120520060893000_11.3.e043612.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202789"},{"key":"2025120520060893000_11.3.e043612.26","first-page":"37","article-title":"Quantifying opportunities to affect diabetes management in the community","volume":"139","author":"Shiu","year":"2006","journal-title":"Can Pharm J"},{"key":"2025120520060893000_11.3.e043612.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.09.017"},{"key":"2025120520060893000_11.3.e043612.28","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.10.1149"},{"key":"2025120520060893000_11.3.e043612.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2008.07434.x"},{"key":"2025120520060893000_11.3.e043612.30","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.21.2355"},{"key":"2025120520060893000_11.3.e043612.31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.2042-7174.2000.tb01002.x","article-title":"Extended adherence support by community pharmacists for patients with hypertension: a randomised controlled trial","volume":"8","author":"Blenkinsopp","year":"2011","journal-title":"International Journal of Pharmacy Practice"},{"key":"2025120520060893000_11.3.e043612.32","doi-asserted-by":"publisher","DOI":"10.3109\/10601333.2010.539230"},{"key":"2025120520060893000_11.3.e043612.33","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.16.1939"},{"key":"2025120520060893000_11.3.e043612.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1520-037X.2006.05339.x"},{"key":"2025120520060893000_11.3.e043612.35","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.399"},{"key":"2025120520060893000_11.3.e043612.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.528"},{"key":"2025120520060893000_11.3.e043612.37","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.59"},{"key":"2025120520060893000_11.3.e043612.38","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/1715163517701109","article-title":"Cost-Effectiveness of pharmacist care for managing hypertension in Canada","volume":"150","author":"Marra","year":"2017","journal-title":"Can Pharm J"},{"key":"2025120520060893000_11.3.e043612.39","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1715163519851822","article-title":"Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the R\n                  x\n               EACH study","volume":"152","author":"Al Hamarneh","year":"2019","journal-title":"Can Pharm J"},{"key":"2025120520060893000_11.3.e043612.40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1715163518779092","article-title":"Pharmacist prescribing and care improves cardiovascular risk, but what do patients think? A substudy of the R \n                  x\n                EACH study","volume":"151","author":"Al Harmarneh","year":"2018","journal-title":"Can Pharm J"},{"key":"2025120520060893000_11.3.e043612.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2018.02.022"},{"key":"2025120520060893000_11.3.e043612.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2016.07.510"},{"key":"2025120520060893000_11.3.e043612.43","first-page":"S1","article-title":"Clinical practice guidelines for the prevention and management of diabetes in Canada","volume":"2018","author":"Canada","year":"2018","journal-title":"Canadian Journal of Diabetes"},{"key":"2025120520060893000_11.3.e043612.44","doi-asserted-by":"publisher","DOI":"10.1042\/cs1010671"},{"key":"2025120520060893000_11.3.e043612.45","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2013-303640"},{"key":"2025120520060893000_11.3.e043612.46","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jcjd.2017.08.244","article-title":"The Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Adult Patients with Type 2 Diabetes: The Multicentre Randomized Controlled R\n                  x\n               EACH Trial","volume":"41","author":"Al Hamarneh","year":"2017","journal-title":"Can J Diabetes"},{"key":"2025120520060893000_11.3.e043612.47","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.4.421"},{"key":"2025120520060893000_11.3.e043612.48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13075-019-1817-y","article-title":"Awareness and perceived risk of cardiovascular disease among individuals living with rheumatoid arthritis is low: results of a systematic literature review","volume":"21","author":"Ghosh-Swaby","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025120520060893000_11.3.e043612.49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.015464"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-043612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:06:23Z","timestamp":1764993983000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-043612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,24]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1136\/bmjopen-2020-043612"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-043612","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}